Primary graft infections

Size: px
Start display at page:

Download "Primary graft infections"

Transcription

1 Primary graft infections William H. Edwards, Jr., M.D., Raymond S. Martin III, M.D., Judith M. Jenkins, 1LN., M.S.N., William H. Edwards, Sr., M.D., and Joseph L. Mtflherin, Jr., M.D., Nashville, Tenn. An amputation rate of 8% to 52% and a mortality rate of 13% to 58% make vascular prosthetic graft infections the most dreaded complication facing a vascular surgeon. In I978 a randomized prospective double-blind study reported a statistically significant decrease in wound infections in patients treated with prophylactic antibiotics whereas the graft infection difference only approached statistical significance. The present study reviews 2614 arterial prosthetic grafts implanted from January 1975 through June Twenty-four patients were identified as having a prosthetic graft infection, yielding an overall infection rate of 0.92%. Staphylococcus aureus was the most common organism, occurring in one third of the cases. The most common graft material was polytetrafluoroethylene (PTFE) (33%) followed by Dacron (29%), composite PTFE and Dacron (20%), and umbilical vein grafts (9%). Diabetes was a common factor in one third of the patients. Symptoms of infection were present in 15 patients (63%) within 3 months of operation, with 11 patients showing symptoms within 30 days. The longest interval between operation and onset of symptoms was 48 months. Prophylactic antibiotics were administered to 22 of the24 patients, but in only 7 of the 22 (29.5%) were they given according to our usual practice. All patients required removal of the infected prosthesis, with limb loss in 17% and death in 17%. (J VAsc SURG 1987;6:235-9.) Infection of a vascular prosthesis is one of the most dreaded complications that faces a vascular surgeon. The incidence of this problem has been reported in the recent literature to range from 0.8% to 2.6%. 19 Even more devastating are the high mortality rates, ranging from 13% to 58% 1~'7'9-11 and the high rate of subsequent amputations, ranging from 8% to 52%* that occur after this complication. Nine years ago, a prospective double-blind trial of prophylactic antibiotics in vascular surgical patients was reported. 13 Although this study showed a statistically significant decrease in wound infections in patients treated with prophylactic antibiotics, the graft infection difference between the treated and control groups only approached statistical significance. The present study was undertaken to review our experience with arterial prosthetic grafts that became infected after implantation and to review factors that might lead to lower graft infection rates. From the Department of Surgery, St. Thomas Hospital and the Section of Surgical Sciences, Vanderbilt University Medical Center (Drs. Edwards, Jr., Martin, Edwards, Sr., and Mulherin), and the Edwards-Eve Clinic Association (Ms. Jenkins). Presented at the Eleventh Annual Meeting of the Southern Association for Vascular Surgery, Scottsdale, Ariz., Jan , Reprint requests: William H. Edwards, Sr., M.D., Suite 205, 4230 Harding Rd,, Nashville, TN *References 1, 2, 4, 7, 9, 10, 12. MATERIAL AND METHODS From January 1975 through June 1986, 2614 arterial prosthetic grafts were implanted in the aortic, iliac, femoral, and popliteal-tibial positions. All brachiocephalic, visceral artery, vascular access, and patch prostheses are excluded. The Infectious Disease Database was used to identify any patient on the vascular surgical service with any positive wound culture (graft infections are not specifically coded). This yielded approximately 200 patients whose charts were reviewed for identification of Szilagyi grade III graft infections on the basis of purulent or culturepositive perigraft fluid.1 All graft enteric erosions and graft enteric fistulas were excluded from study. In addition, the operative time was obtained for 100 consecutive aortobifemoral bypass grafts and femoropopliteal/tibial bypass grafts performed during 1985 and 1986 with prosthetic material or composite graft and autogenous tissue. Statistical analysis was performed by means of the Mann-Whitney test. RESULTS Twenty-four patients (21 men and three women) were identified, giving an overall graft infection rate of 0.92%. The average age of patients at the time of graft implantation was 61.6 years (range 30 to 75 years). Atherosclerotic disease was the indication for operation in all patients. Risk factors for infection (Table I) were found in 19 patients (79%). Post- 235

2 236 Edwards et al. Journal of VASCULAR SURGERY Table I. Risk factors for infection _No. % Wound with infection 8 33 Diabetes 8 33 Distal ulcer or gangrene 5 20 Multiple limb revascularization 5 20 (>2) Graft thrombosis Emergency operation Table II. Graft insertion sites No. % Femoropopliteal 8 33 Femorotibial 8 33 Aortobifemoral* 5 21 Primary femoral artery replacement 1 4 Extra-anatomic bypass 2 9 Total 24 *Two patients required urgent femoropopliteal bypass at same hospitalization. operative wound infection and diabetes were the most frequent predisposing factors. Preoperative cultures of distal ulcers were obtained in three cases and in only one case was the graft infection identical. Fig. 1 presents the infection rate per year as a function of the number of grafts inserted and Table II presents the sites of insertion. In three cases, other operations were added in addition to the vascular bypass (lumbar sympathectomy, inguinal hernia repair, and cholecystectomy); in two of the aortobifemoral bypass cases, urgent femoropopliteal bypass was required. In five cases, use of a previously inserted aortofemoral graft as a donor vessel for distal bypass resulted in infection of both the distal bypass and at least one limb of the aortofemoral graft. Two deaths and one hip disarticulation for ischemia and infection ensued from this complication. There were no intraabdominal graft infections in the 2614 cases. In 20 cases the groin was the primary site of infection. Four patients had a graft infection at the distal insertion site. In all cases of graft infection during the period under study, the operation involved a groin incision. The most common graft material involved was polytetrafluoroethylene (PTFE) (33%), followed by Dacron (29%), and then human umbilical vein grafts (9%). The remainder of the infections involved composite PTFE and Dacron (20%) or composite synthetic graft and vein (9%). Staphylococcus aureus was the most common offending organism, occurring in one third of the cases (Table III). Symptoms of infection became apparent in 15 of the cases less than 3 months after operation, with 11 cases occurring in the first 30 days. Five more infections occurred before 6 months and four occurred after 6 months. The longest interval between operation and onset of infection was 48 months. The most common symptom of infection was purulent wound drainage (48%). This was followed by acute and chronic bleeding (26%), fever (17%), false aneurysm (12.5%), and pain (8%). Confirmation of prophylactic antibiotic administration was obtained in 22 of 24 cases. One case was randomly assigned to a control group for study and in the other case the medical record was incomplete. In only 7 of the 22 remaining cases were the prophylactic antibiotics administered according to the recommendations of the hospital Infectious Disease Department. Cefazolin doses at the anesthetic induction were repeated every 4 hours during the operation and continued every 6 hours for a total of 24 hours, x s,14 The mean operative time was calculated for both the infected aortofemoral bypass patients and femoropopliteal/tibial patients. The mean operative time for the past 100 consecutive aortobifemoral bypass patients and femoropopliteal/tibial bypass patients was likewise calculated. The two groups were then compared for a difference in operative time with the Mann-Whitney test of significance. The infected aortobifemoral bypass patients had a mean operative time of 245 _+ 58 minutes compared with the population of 100 consecutive aortobifemoral bypass patients whose mean time was 196 _+ 55 minutes (p < 0.05). Likewise, the group of femoropopliteal/tibial bypass patients was compared with 100 consecutive patients with similar operations; means were 168 _+ 63 minutes and 132 _+ 57 minutes, respectively (p < 0.02). All patients eventually required removal of the infected graft with autogenous tissue repair of the native vessel, autogenous tissue bypass through the infected bed, or bypass through clean tissue planes with prosthetic material. Table IV reviews the results obtained, revealing a mortality rate of 17% and an amputation rate of 17%. Three of the four deaths were due to uncontrolled sepsis and one was due to an acute superior mesenteric infarction. The high death rate after the infection of femorodistal bypass grafts was the result of proximal spread along a previously placed aortofemoral graft, which acted as the donor vessel for the distal bypass. DISCUSSION Use of prophylactic antibiotics. The routine use of prophylactic antibiotics in vascular surgery has

3 Volume 6 Number 3 September 1987 Primary graj~ infections CL E : Year of Implantation Fig, 1. Graft infections per year. contributed to decreasing the graft infection rate. In the randomized study conducted in which prophylactic antibiotics were compared with placebo, a significant decrease in postoperative wound infection in the treated group was found) 3 The study was halted before the graft infection rate reached significance (p = 0.062). It was believed that the continued exposure of patients to placebo was not warranted to prove that graft infections might be reduced. Many authors consider wound infections to be a predisposing factor to deep graft infection and in fact this was the case in one third of our patients in the present study. 7,932 Once the decision has been made to use prophylactic antibiotics, we believe that it is equally important that they be administered appropriately. Principles important to their use include an agent effective against most potential pathogens, administration at the time of anesthetic induction, and recurrent doses to maintain serum levels throughout the operative procedure. ~4 Kaiser et al.~4"~s reported that deviations from these principles can lead to a higher wound infection rate. Investigation of an increasing wound infection rate on the vascular surgical service in the past uncovered minor deviations from these principles. A cephalosporin of shorter half-life was being substituted and probably led to inadequate serum levels on prolonged procedures. ~ At the same time a random review of charts revealed that the time between "on call" cephalosporin and the surgical procedure had increased from 91 to 131 minutes. In addition, 15% of the patients surveyed had in excess of 3 hours between the administration of the antibiotic prophylaxis and the onset of the surgical procedure. ~4,~s In the present study, prophylactic anti- Table Ill. Culture results No. of patients % Staphylococcus aureus 7 29 No growth 5 21 Proteus mirabilis 3 13 Mixed gram positive 3 13 and gram negative Anaerobes 2 8 Staphylococcus epidermidis 1 4 Pseudomonas aeruginosa 1 4 Serra~ sp. 1 4 Enterobacter cloaca 1 4 Total 24 biotics were appropriately administered in only 29.5% of the patients in whom a graft infection occurred. Preparation of the operative site. Skin cleansing and disinfection is an integral part of every surgical procedure. This becomes even more important when operations are performed in the groins. All patients received the standard antiseptic scrub and preparation with povidone-iodine solutions the night before surgery. In the previous study of antibiotic prophylaxis, a significant difference in wound infection rate between hexachlorophene-ethanol skin preparation (10.3%) and the patients receiving a povidoneiodine preparation (2.8%) was seen. In addition, there was an even more marked difference in the wound infection rate in the patients who received hexachlorophene-ethanol skin preparation when they were broken down into placebo and antibiotictreated groups. The placebo group had an extremely high wound infection rate of 18.9% vs. the treated

4 238 Edwards et al. Journal of VASCULAR SURGERY Table IV. Results of primary graft infections No Site of insertion No. Infections amputation Amputation Deaths Aortic/aortoiliac Aortofemoral (0.47%) 2 (40%) 2 (40%) 1 (20%) Femoropopliteal/tibial (2.9%) 12 (70%) 2 (12%) 3 (18%) Extra-anatomic (0.99%) 2 (100%) 0 0 Total (0.92%) 16 (66%) 4 (17%) 4 (17%) group with no wound infections, suggesting an even greater protection of prophylactic antibiotics.is If the groin is the "dirtiest" area in which vascular surgeons perform operations and prophylactic antibiotics seem to be more effective when the wound infection rate is higher, then their proper use takes on even greater importance when an operation in the groin is contemplated. Several authors have noted a disproportionate infection rate when a groin incision is involved in the implantation of a vascular prosthesis. 1-4,6,9,11 Most of these infections probably result from the inability to prepare and drape this area, as well as the moisture and constant motion that occur postoperatively. It is important to avoid skin contamination of the graft and the use of plastic skin drapes on all cases involving the abdomen and groins is standard practice with the higher incidence of infections found in the femoropopliteal/tibial group. We began to use circumferential plastic leg drapes in all distal bypass procedures in which it was known that a synthetic graft was required. Role of local and remote wound contamination. Arteriography performed in the same groin as the vascular prosthesis implantation has been thought by some authors to contribute to a higher rate of groin wound complications. 6 Routine use of translumbar aortography for investigation of aortoiliac atherosclerotic disease and needle femoral arteriography when there is suspicion of distal disease avoids this problem. Personal performance of these procedures assures adequate visualization of the arterial tree. These procedures are performed by members of a vascular team of attending physicians and residents. When catheter studies are carried out from the groin, every attempt is made to perform the operative procedure the next day. Remote site infections have been thought to be important in the genesis of wound infections and perioperative bacteremia..6 There are anecdotal reports in the literature of remote site infections (primarily urinary) causing graft infections. Accordingly, the active investigation of even minimal pyuria pre- operatively and institution of antibiotic treatment as soon as cultures are obtained should be standard. If an infection is confirmed, then therapeutic antibiotics are used and adjusted according to the organism and sensitivity. The effect of operative time. Surgical wound infection rates have previously been correlated with duration of operation and in at least one report, it was thought that the length of operation was a reflection of operative technique. 9,1r Expeditious completion of surgical procedures with two dissection and anastomotic teams operating simultaneously when the case involves two groins or a groin and a leg will keep open wound times to a minimum. In the present study, a statistically significant difference was found between the operative times in the respective infected aortobifemoral and femoropopliteal/tibial patients compared with a group of patients that are comparable except for date of operation. The two groups may not be completely comparable as the skills of the surgeons involved have probably improved during the 11.5 years of the study and that may have contributed to a shorter operative time in the past 100 patients. Lorentzen et al.9 reported median operative times of 310 minutes for infected bifurcated grafts and a corresponding time in femoral peripheral reconstructions of 295 minutes with infection rates of 2.6% for a group of patients in Denmark. Shorter operative times through the use of the two-team approach have contributed to maintenance of a low graft infection rate in the patients reported herein. The effect of secondary operations. Groins in which a previous graft implantation was performed afford special challenges. It is essential in all surgical procedures to use Halstedian principles of operative technique. Never is this more important than in groins in which operations have been repeated, where there is dense scar tissue, increased bleeding, lymphatic leak, and frequently nonfunctioning graft material already implanted. In the present study, 20% of patients had had more than two revascularizations of their distal extremity. In addition, six patients suf-

5 Volume 6 Number 3 September 1987 Primary graft infections 239 fered proximal extension of their infection to previously implanted graft material, resulting in significant morbidity and mortality. In many cases it is necessary to use the proximal graft as the donor artery. An alternative approach to the groin is to join the graft onto the native artery distal to the donor graft, thereby avoiding disruption of the perigraft fibrous capsule when the anastomoses are constructed. Treatment of infected grafts. Prevention is the best treatment of vascular prosthetic graft infections. When an infection occurs, authors disagree on the most appropriate treatment. All patients in the study ultimately required excision of the infected portion of the graft and bypass through clean tissue planes, bypass with autogenous tissue through the infected bed, or repair of the native vessel with autogenous tissue. This treatment led to an overall amputation rate of 17% and a mortality rate of 17%. Sixty-six percent of the patients recovered completely with limb intact. Local wound irrigation has been used if suture lines are not exposed. Prosthetic vascular graft infections are fortunately a rare event. Our infection rate of 0.92% compares favorably with that reported in the literature, which in recent years is approximately 2%. Vascular graft infections, despite their low incidence, remain a significant problem, challenging all vascular surgeons. Detection and treatment require perseverance and ingenuity. Only through continued aggressive prevention will the rate of graft infection be decreased. Prevention of prosthetic graft infections through future research should continue. Emphasis should be placed on chemical sterilization of the contaminated wound with more effective antibiotic prophylaxis, research into control of routes of wound contamination, and modification of the host immune system. REFERENCES 1. Szilagyi DE, Smith RF, Elliott JP, Vrandecic MP. Infection in arterial reconstruction with synthetic grafts. Ann Surg 1972; 176: Goldstone J, Moore WS. Infection in vascular prostheses: clinical manifestations and surgical management. Am J Surg 1974;128: Jamieson GG, DeWeese JA, Rob CG. Infected arterial grafts. Ann Surg 1975;181: Liekweg WG, Greenfield LJ. Vascular prosthetic infections: collected experience and results of treatment. Surge~, 1977; 81: Ernst CB, Campbell Jr HC, Daugherty ME, Sachatello CR, Griffen WO. Incidence and significance of intraoperative bacterial cultures during abdominal aortic aneurysmectomy. Ann Surg 1977;185: Landreneau MD, Raju S. Infections after elective bypass surgery for lower limb ischemia: the influence of preoperative transcutaneous arteriography. Surgery 1981;90: Bunt TJ. Synthetic vascular graft infections. I. Graft infections. Surgery 1983;93: Bennion RS, Hiatt JR, Williams RA, Wilson SE. Surgical management of unilateral groin infection after aortofemoral bypass. Surg Gynecol Obstet 1983;156: Lorentzen JE, Nielsen OM, Arendrup H, et al. Vascular graft infection: an analysis of sixty-two graft infections in 2411 consecutively implanted synthetic vascular grafts. Surgery 1985;98: Ehrenfeld WK, Wilbur BG, Olcott CN, Stoney RJ. Autogenous tissue reconstruction in the management of infected prosthetic grafts. Surgery 1979;85: Bouhoutsos J, Chavatzas D, Martin P, Morris T. Infected synthetic arterial grafts. Br J Surg 1974;61: Reilly LM, Altman H, Lusby RJ, Kersh RA~ Ehrenfeld WK, Stoney RJ. Late results following surgical management of vascular graft infection. J VAsc SURG 1984;1: Kaiser AB, Clayson KR, Mulherin Jr JL, et al. Antibiotic prophylaxis in vascular surgery. Ann Surg 1978;188: Kaiser A. Zero infection rate: an achievable irreducible minimum in clean surgery? Infect Control 1986;7: Kaiser A. Effective and creative surveillance and reporting of surgical wound infections. Infect Control 1982;3: Edwards LD. The epidemiology of 2056 remote site infections and 1966 surgical wound infections occurring in 1865 patients: a four-year study of 40,923 operations at Rush- Presbyterian-St. Luke's Hospital, Chicago. Ann Surg 1976; 184: Cruse PJE, Foord R. A five-year prospective study of 23,649 surgical wounds. Arch Surg 1973;107:206-9.

Vascular Graft Sepsis

Vascular Graft Sepsis Vascular Graft Sepsis Nadraj G Naidoo Vascular & Endovascular Surgery Unit Department of Surgery Groote Schuur Hospital University of Cape Town Definition: Vascular graft sepsis Sepsis involving all or

More information

University Hospital. Parkland Hospital

University Hospital. Parkland Hospital University Hospital Parkland Hospital Contemporary Management of Aortic Graft Infections R. James Valentine, MD Division of Vascular and Endovascular Surgery UT Southwestern Medical Center Dallas, Texas

More information

Infectious Complications in Vascular Patients

Infectious Complications in Vascular Patients Infectious Complications in Vascular Patients Shireesha Dhanireddy, MD Medical Director, Infectious Disease Clinic Harborview Medical Center Associate Professor, Department of Medicine University of Washington

More information

Prosthetic Vascular Graft Infection

Prosthetic Vascular Graft Infection Prosthetic Vascular Graft Infection Charito Love, MD Division of Nuclear Medicine & Molecular Imaging North Shore Long Island Jewish Health System Manhasset & New Hyde Park, New York Prosthetic Vascular

More information

Aortic Graft Infection- Contemporary Management of a Resurgent Problem

Aortic Graft Infection- Contemporary Management of a Resurgent Problem Aortic Graft Infection- Contemporary Management of a Resurgent Problem Peter F. Lawrence, MD Professor and Chief Division of Vascular Surgery University of California Los Angeles Incidence of Aortic Graft

More information

Vascular graft infection in aortoiliac and aortofemoral bypass surgery: clinical presentation, diagnostic strategies and results of surgical treatment

Vascular graft infection in aortoiliac and aortofemoral bypass surgery: clinical presentation, diagnostic strategies and results of surgical treatment ORIGINAL ARTICLE Vascular graft infection in aortoiliac and aortofemoral bypass surgery: clinical presentation, diagnostic strategies and results of surgical treatment C. Soetevent 1, P.L. Klemm 2, A.F.H.

More information

D. L. Jicha, MD, * L. M. Reilly, MD, L. M. Kuestner, MD,:~ and R. J. Stoney, MD, San Francisco, Calif.

D. L. Jicha, MD, * L. M. Reilly, MD, L. M. Kuestner, MD,:~ and R. J. Stoney, MD, San Francisco, Calif. Durability of cross-femoral grafts aortic graft infection: The fate of autogenous conduits after D. L. Jicha, MD, * L. M. Reilly, MD, L. M. Kuestner, MD,:~ and R. J. Stoney, MD, San Francisco, Calif. Purpose:

More information

University of Groningen. Improving diagnostic accuracy in aortic prosthetic graft infection Saleem, Rani

University of Groningen. Improving diagnostic accuracy in aortic prosthetic graft infection Saleem, Rani University of Groningen Improving diagnostic accuracy in aortic prosthetic graft infection Saleem, Rani IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

Use of antibiotic-loaded polymethylmethacrylate beads for the treatment of extracavitary prosthetic vascular graft infections

Use of antibiotic-loaded polymethylmethacrylate beads for the treatment of extracavitary prosthetic vascular graft infections From the Society for Clinical Vascular Surgery Use of antibiotic-loaded polymethylmethacrylate beads for the treatment of extracavitary prosthetic vascular graft infections Patrick A. Stone, MD, Paul A.

More information

A UNIQUE POLYESTER DRUG/DEVICE VASCULAR GRAFT INTERGARD HEPARIN

A UNIQUE POLYESTER DRUG/DEVICE VASCULAR GRAFT INTERGARD HEPARIN A UNIQUE POLYESTER DRUG/DEVICE VASCULAR GRAFT INTERGARD HEPARIN FACTS ON INTERGARD HEPARIN Most frequent causes of vascular graft failure and associated limb loss 1 Graft occlusion due to the development

More information

A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network

A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION Vascular Implant Surveillance & Interventional Outcomes Network Jack L. Cronenwett, MD Medical Director, Society for Vascular

More information

Antibiotic-loaded polymethylmethacrylate beads for the treatment of extracavitary vascular surgical site infections

Antibiotic-loaded polymethylmethacrylate beads for the treatment of extracavitary vascular surgical site infections From the Eastern Vascular Society Antibiotic-loaded polymethylmethacrylate beads for the treatment of extracavitary vascular surgical site infections Patrick A. Stone, MD, Albeir Y. Mousa, MD, Stephen

More information

Comparison of endovascular and conventional vascular prostheses in an experimental infection model

Comparison of endovascular and conventional vascular prostheses in an experimental infection model Comparison of endovascular and conventional vascular prostheses in an experimental infection model Richard E. Parsons, MD, Luis A. Sanchez, MD, Michael L. Marin, MD, ILaren A. Holbrook, MD, Peter L. Faries,

More information

INSTRUCTIONS FOR USE FOR:

INSTRUCTIONS FOR USE FOR: INSTRUCTIONS FOR USE FOR: en English INSTRUCTIONS FOR USE GORE ENFORM INTRAPERITONEAL BIOMATERIAL Carefully read all instructions prior to use. Observe all instructions, warnings, and precautions noted

More information

A preliminary study of prosthesis damage by laser energy. James M. Seeger, M.D., George S. Abela, M.D.,* and Nina Klingman, B.S., Gainesville, Fla.

A preliminary study of prosthesis damage by laser energy. James M. Seeger, M.D., George S. Abela, M.D.,* and Nina Klingman, B.S., Gainesville, Fla. Laser radiation in the graft stenosis treatment of prosthetic A preliminary study of prosthesis damage by laser energy James M. Seeger, M.D., George S. Abela, M.D.,* and Nina Klingman, B.S., Gainesville,

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our

More information

Policies Concerning Survival Surgery of Mice

Policies Concerning Survival Surgery of Mice Policies Concerning Survival Surgery of Mice Date approved: October 25, 2016 Purpose This document details the minimum standards for survival (recovery) surgery in all laboratory rodent species. Responsibility

More information

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3. Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.1; 14 Apr 2016) VI.2 VI.2.1 Elements for a Public Summary Overview of

More information

ProCol Vascular Bioprosthesis

ProCol Vascular Bioprosthesis Instructions for Use 1. DEVICE DESCRIPTION The ProCol Vascular Bioprosthesis is derived from bovine mesenteric vein processed with glutaraldehyde. Collateral branches are ligated with surgical suture and

More information

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.

Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D. Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin

More information

Optimizing Breast Pocket Irrigation: An in Vitro Study and Clinical Implications

Optimizing Breast Pocket Irrigation: An in Vitro Study and Clinical Implications Cosmetic Optimizing Breast Pocket Irrigation: An in Vitro Study and Clinical Implications William P. Adams, Jr., M.D., W. Chad H. Conner, B.A., Fritz E. Barton, Jr., M.D., and Rod J. Rohrich, M.D. Dallas,

More information

PREVELEAK Surgical sealant

PREVELEAK Surgical sealant PREVELEAK Surgical sealant Rx only Instructions for Use DEVICE DESCRIPTION PREVELEAK Surgical sealant (PREVELEAK) is a sealant developed to seal suture holes formed during surgical repair of the circulatory

More information

A review of Dr. Dinakar Golla s clinical research with AdMatrix surgical grafts for soft tissue repair

A review of Dr. Dinakar Golla s clinical research with AdMatrix surgical grafts for soft tissue repair TEAMeffort: Using aggressive surgical techniques in combination with AdMatrix (Lattice Biologics acellular dermal scaffold product) to heal difficult and persistent wounds A review of Dr. Dinakar Golla

More information

LINC James F. McKinsey, M.D.

LINC James F. McKinsey, M.D. Two-Year Evaluation of Fenestrated and Parallel Branch Endografts for the Treatment of Juxtrarenal, Suprarenal and Thoracoabdominal Aneurysms at a Single Institution LINC 2018 James F. McKinsey, M.D. The

More information

Branched Grafts for Thoracoabdominal Aneurysms: Off-Label Use of FDA-Approved Devices

Branched Grafts for Thoracoabdominal Aneurysms: Off-Label Use of FDA-Approved Devices 471 TECHNICAL NOTE Branched Grafts for Thoracoabdominal Aneurysms: Off-Label Use of FDA-Approved Devices Karthik, MD Emory University School of Medicine, Atlanta, Georgia, USA. Purpose: To report off-label

More information

INSTRUCTIONS FOR USE FOR:

INSTRUCTIONS FOR USE FOR: INSTRUCTIONS FOR USE FOR: B I O M A T E R I A L en English INSTRUCTIONS FOR USE FOR GORE SYNECOR INTRAPERITONEAL BIOMATERIAL INDICATIONS The GORE SYNECOR Intraperitoneal Biomaterial device is intended

More information

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician.

CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician. TM CAUTION: U.S. Federal law restricts this device to sale by or on the order of a licensed physician. TABLE OF CONTENTS Section Port Styles 4 Description 5 Indications 5 Contraindications 5-6 Information

More information

Xpansion. Reimbursement & Coding Guide

Xpansion. Reimbursement & Coding Guide Xpansion Reimbursement & Coding Guide 1 2 The Xpansion Micro-Autografting Kit Reimbursement and Coding Guide The Xpansion micro-autografting kit allows for small, autologous donor sites to be used to cover

More information

vacuum-assisted closure VAC

vacuum-assisted closure VAC 14 689 693 2005 vacuum-assisted closure V 25 vacuumassisted closure V 14.6 19 9 V 14 689 693 2005 arteriosclerosis obliterans: SO vacuum-assisted closure V SO 25 Table 1 25 19 Tel: 0166-68-2494 078-8510

More information

4/25/2009. Other 8% Thrombosis? Stenosis 8% 74% Infection 10%

4/25/2009. Other 8% Thrombosis? Stenosis 8% 74% Infection 10% Hells and Hosannas of Vascular Access Or what to do in some Hellish Vascular Access situations Marc H Glickman MD Eastern Virginia Medical School Sentara Medical Group Norfolk, Virginia, USA Who is the

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and

More information

Advancing the Open Ventral Hernia Repair Experience

Advancing the Open Ventral Hernia Repair Experience Advancing the Open Ventral Hernia Repair Experience SOFT TISSUE REPAIR Right Procedure. Right Product. Right Outcome. Hernia Repair Fixation Absorbable Fixation System Optimized Design for Open Ventral

More information

University of Groningen. Improving diagnostic accuracy in aortic prosthetic graft infection Saleem, Rani

University of Groningen. Improving diagnostic accuracy in aortic prosthetic graft infection Saleem, Rani University of Groningen Improving diagnostic accuracy in aortic prosthetic graft infection Saleem, Rani IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish

More information

Antibiotic irrigation and conservative for major aortic graft infection

Antibiotic irrigation and conservative for major aortic graft infection Antibiotic irrigation and conservative for major aortic graft infection surgery G. E. Morris, DM, MCh, FRCS, P. J. Friend, MA, FRCS, D. J. Vassallo, FRCS, RAMC, M. Farrington, MA, MRCPath, S. Leapman,

More information

AHIMA supports the proposed changes to ICD-10-PCS that were presented at the March 9 th C&M Committee meeting.

AHIMA supports the proposed changes to ICD-10-PCS that were presented at the March 9 th C&M Committee meeting. VIA ELECTRONIC MAIL Patricia Brooks, RHIA Centers for Medicare & Medicaid Services CMM, HAPG, Division of Acute Care Mail Stop C4-08-06 7500 Security Boulevard Baltimore, Maryland 21244-1850 Dear Ms. Brooks:

More information

Ventrio ST Hernia Patch featuring Sepra Technology

Ventrio ST Hernia Patch featuring Sepra Technology Ventrio ST Hernia Patch featuring Sepra Technology Sepra Technology An extensively studied barrier with more than 10 publications and used clinically since 2007. Unique hydrogel barrier swells to minimize

More information

Prevention of vascular prosthetic infection with an antibiotic-bonded Dacron graft

Prevention of vascular prosthetic infection with an antibiotic-bonded Dacron graft Prevention of vascular prosthetic infection with an antibiotic-bonded Dacron graft William B. Shue, BA, t Sharon C. Worosilo, MS, Anthony P. Donetz, B$, Stanley Z. Trooskin, MD, Richard A. Harvey, PhD,

More information

31st 31 Annual Controversies, Problems a nd and and Techniques Techniques in

31st 31 Annual Controversies, Problems a nd and and Techniques Techniques in 31 st Annual Controversies, Problems and Techniques in Surgery Michael J. Rosen MD, FACS Professor of Surgery Director, Cleveland Clinic Comprehensive Hernia Center Cleveland Clinic Foundation Cleveland

More information

Vascular. Making Best Use of Trinias Applications for Lower Extremity Interventional Procedures. 1. Introduction

Vascular. Making Best Use of Trinias Applications for Lower Extremity Interventional Procedures. 1. Introduction Vascular Making Best Use of Trinias Applications for Lower Extremity Interventional Procedures Yasuhiro Takahashi, M.D. Department of Cardiology, The Fraternity Memorial Hospital Yasuhiro Takahashi 1.

More information

RESEARCH DIAGNOSTICS PREVENTION TREATMENT

RESEARCH DIAGNOSTICS PREVENTION TREATMENT RESEARCH DIAGNOSTICS PREVENTION TREATMENT Implant- and Biofilm-Related Infections US National Institutes of Health Biofilms are medically important, accounting for over 80% of microbial infections in the

More information

Differential effects of a gram-negative and a gram-positive infection on autogcnous and prosthetic grafts

Differential effects of a gram-negative and a gram-positive infection on autogcnous and prosthetic grafts Differential effects of a gram-negative and a gram-positive infection on autogcnous and prosthetic grafts Kevin J. Geary, MD, Zygrnunt M. Tomkiewicz, MD, FACP, Howard N. Harrison, PhD, William M. Fiore,

More information

The Cat s Out of the Bag: Microbiological Investigations of Acute Transfusion Reactions.

The Cat s Out of the Bag: Microbiological Investigations of Acute Transfusion Reactions. The Cat s Out of the Bag: Microbiological Investigations of Acute Transfusion Reactions. Philippe Lagacé-Wiens, MD FRCPC, DTM&H plagacewiens@sharedhealthmb.ca COI declaration I have no conflicts, real

More information

Novel BioResorbable Vascular Platforms from India

Novel BioResorbable Vascular Platforms from India DEEP DIVE SESSION: Lower limb interventions (part II) Femoropopliteal, drug-eluting devices, and new technologies Time 11:55am to 12:01pm Novel BioResorbable Vascular Platforms from India Dr. Vimal Someshwar

More information

Open Bypass for Limb Salvage: What are the Options when there is no Saphenous Vein

Open Bypass for Limb Salvage: What are the Options when there is no Saphenous Vein Open Bypass for Limb Salvage: What are the Options when there is no Saphenous Vein Russell H. Samson, MD, FACS, RVT Clinical Professor of Surgery Florida State University Medical School Mote Vascular Foundation,

More information

Thoracoscopic Pneumonectomy. 10 th Annual Masters in Minimally Invasive Thoracic Surgery

Thoracoscopic Pneumonectomy. 10 th Annual Masters in Minimally Invasive Thoracic Surgery Thoracoscopic Pneumonectomy 10 th Annual Masters in Minimally Invasive Thoracic Surgery September 22-23, 2017 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery, Duke University

More information

Educational Program on Robotic Gastrectomy

Educational Program on Robotic Gastrectomy Educational Program on Robotic Gastrectomy Representative:Masanori Terashima Division of Gastric Surgery, Shizuoka Cancer Center Ver. 1.0:April 1, 2018 1 Background The surgical support robot, the da Vinci

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS FREQUENTLY ASKED QUESTIONS Table of Contents GORE ACUSEAL Vascular Graft Properties What is the GORE ACUSEAL Vascular Graft?...2 What is unique about the GORE ACUSEAL Vascular Graft?...3 What are the

More information

Identification of Staphylococcus epidermidis vascular graft infections: A comparison of culture techniques

Identification of Staphylococcus epidermidis vascular graft infections: A comparison of culture techniques Identification of Staphylococcus epidermidis vascular graft infections: A comparison of culture techniques Thomas M. Bergamini, MD, Dennis F. Bandyk, MD, Dean Govostis, MD, Raymond Vetsch, MD, and Jonathan

More information

Advancing minimally invasive. therapeutics through novel device. development. Minima y Invasive New Technologies T H E L E O N A M. A N D H A R R Y B.

Advancing minimally invasive. therapeutics through novel device. development. Minima y Invasive New Technologies T H E L E O N A M. A N D H A R R Y B. MIN T Minima y Invasive New Technologies Advancing minimally invasive therapeutics through novel device development T H E L E O N A M. A N D H A R R Y B. C H A R I T A B L E T R U S T he Minimally Invasive

More information

Continuous External Tissue Expander

Continuous External Tissue Expander Continuous External Tissue Expander Facilitates rapid tissue movement to automatically reduce or re-approximate wounds Never needs re-tightening after initial application! 1 Potential Annual Hospital Cost

More information

Endograft limb occlusion and stenosis after ANCURE endovascular abdominal aneurysm repair

Endograft limb occlusion and stenosis after ANCURE endovascular abdominal aneurysm repair Endograft limb occlusion and stenosis after ANCURE endovascular abdominal aneurysm repair F. Noel Parent III, MD, Vasso Godziachvili, MD, George H. Meier III, MD, Frank M. Parker, DO, Kathleen Carter,

More information

Instructions for Use READY TO USE

Instructions for Use READY TO USE READY TO USE Instructions for Use LifeCell Corporation One Millennium Way Branchburg, NJ 08876-3876 1.908.947.1215 1.800.367.5737 Fax: 1.908.947.1089 E-mail: customerservicegroup@lifecell.com www.lifecell.com

More information

FORWARD LOOKING STATEMENT

FORWARD LOOKING STATEMENT FORWARD LOOKING STATEMENT Statements made in this presentation that look forward in time or that express management's beliefs, expectations, hopes or predictions of the future are forward-looking statements

More information

Presenting SURGICEL Powder

Presenting SURGICEL Powder SURGICEL Powder Presenting SURGICEL Powder Built to stop continuous, broad-surface oozing fast1,2 The next generation of SURGICEL Absorbable Hemostats SURGICEL Powder efficiently and effectively controls

More information

1. Until the CE Mark suspension has been lifted, the AFX product should not be implanted in patients.

1. Until the CE Mark suspension has been lifted, the AFX product should not be implanted in patients. 2 Musick Irvine, CA 92618 949 595 7200 endologix.com Field Safety Notice AFX TM Endovascular AAA System: Suspension of CE Mark 29744/29731 and Patient Follow-up Advice Type of Action: Product Codes: Customer

More information

WICHITA STATE UNIVERSITY INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) ANIMAL PROTOCOL FORM

WICHITA STATE UNIVERSITY INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) ANIMAL PROTOCOL FORM WICHITA STATE UNIVERSITY INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) ANIMAL PROTOCOL FORM Date: Principal Investigator: Title of Project: Protocol #: Animal Species: Anticipated Start Date: Anticipated

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the

More information

V. Riambau, MD, PhD. Professor and Chief of Vascular Surgery Division CardioVascular Institute, Hospital Clinic, University of Barcelona

V. Riambau, MD, PhD. Professor and Chief of Vascular Surgery Division CardioVascular Institute, Hospital Clinic, University of Barcelona V. Riambau, MD, PhD Professor and Chief of Vascular Surgery Division CardioVascular Institute, Hospital Clinic, University of Barcelona vriambau@clinic.ub.es Consultant/Advisor Bolton Medical Cordis Bard

More information

Polidocanol Endovenous Microfoam (PEM) Comprehensive Treatment for Great Saphenous Vein System (GSV) Incompetence

Polidocanol Endovenous Microfoam (PEM) Comprehensive Treatment for Great Saphenous Vein System (GSV) Incompetence Polidocanol Endovenous Microfoam (PEM) Comprehensive Treatment for Great Saphenous Vein System (GSV) Incompetence By Ariel D. Soffer, MD, FACC Dr. Ariel David Soffer-Bio NCVH Vein Forum Fellow of the American

More information

PER F ORM ANC E b y d e s i g n. Pioneering TEVAR Therapy, Time and Time Again. CONFORMABLE

PER F ORM ANC E b y d e s i g n. Pioneering TEVAR Therapy, Time and Time Again. CONFORMABLE PER F ORM ANC E b y d e s i g n Pioneering TEVAR Therapy, Time and Time Again. CONFORMABLE T H O R A C I C E N D O P R O S T H E S I S Time-Tested Success For more than 16 years, the GORE TAG Device has

More information

Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis.

Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty Nerurkar J, Wade W E, Martin B C Record Status This is a critical abstract

More information

Anti- THrombosis with Enoxaparin in intubated Adolescents

Anti- THrombosis with Enoxaparin in intubated Adolescents Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question

More information

BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS AT AORN MEETING

BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS AT AORN MEETING FOR IMMEDIATE RELEASE Media Contact Beth Mueller, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS

More information

liquids. 3) Mist/wipe the work surface wiped with disinfectant before conducting surgery.

liquids. 3) Mist/wipe the work surface wiped with disinfectant before conducting surgery. Institutional Animal Care Program Title: RODENT SURVIVAL SURGERY Policy#: IACP 004 Date in Effect: 12/14/07 Rev #: 01 Rev Date: 12/14/12 Rev #: 02 Rev Date: 03/08/13 Rev #: 03 Rev Date: 12/13/13 Rev #:

More information

SYNOPSIS. Clinical Study Report for Study CV Individual Study Table Referring to the Dossier

SYNOPSIS. Clinical Study Report for Study CV Individual Study Table Referring to the Dossier Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: SYNOPSIS Clinical Study

More information

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2

The Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2 News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes

More information

Catheter-related infections: practical aspects in 2003

Catheter-related infections: practical aspects in 2003 Catheter-related infections: practical aspects in 2003 A joint meeting of the Société Belge d'infectiologie et de Microbiologie Clinique / Belgische Vereniging voor Infectiologie en Klinische Microbiologie

More information

Comparing Traditional Culture Methods and New Molecular Testing Techniques to Analyze Biofilm Composition on Uninfected IPPs

Comparing Traditional Culture Methods and New Molecular Testing Techniques to Analyze Biofilm Composition on Uninfected IPPs Comparing Traditional Culture Methods and New Molecular Testing Techniques to Analyze Biofilm Composition on Uninfected IPPs Martin S. Gross 1, Gerard D. Henry 2 1: Dartmouth-Hitchcock Medical Center;

More information

Biological Prostheses

Biological Prostheses SAPIENZA UNIVERSITA DI ROMA EHS Dipartimento di Chirurgia Generale Paride Stefanini U.O.C. di Chirurgia Generale D e Day Surgery (Direttore: Prof. P. Negro) PRG M Chirurgia della Parete Addominale (Prof.

More information

3 Phases of Investigation

3 Phases of Investigation Part I: The scientific setting - December 30, 2009, 1 3 Phases of Investigation As discussed in Chapter 1, science is adversarial; scientists should consider all possible hypotheses, and only eliminate

More information

TRUFILL DCS ORBIT Detachable Coil System

TRUFILL DCS ORBIT Detachable Coil System ORBIT Conforming to Your Complex Needs Excellent Conformability and Concentric Filling for Outstanding Packing Density ORBIT Full range of Mini Complex and new Tight Distal Loop Technology coils Our Complex

More information

Decide, guide, treat and confirm: The Philips Volcano CLI solution

Decide, guide, treat and confirm: The Philips Volcano CLI solution Decide, guide, treat and confirm: The Philips Volcano CLI solution Trademarks are the property of Koninklijke Philips N.V. or their respective owners Critical Limb Ischemia Affects the Lives of Many Patients

More information

Modular branched endograft system for aortic aneurysm repair: evaluation in a human cadaver circulation model

Modular branched endograft system for aortic aneurysm repair: evaluation in a human cadaver circulation model Modular branched endograft system for aortic aneurysm repair: evaluation in a human cadaver circulation model Vascular and Endovascular Surgery. 2007 41: 126 9 M.A.M. Linsen A.W.F. Vos J. Diks J.A. Rauwerda

More information

Clinical Data Evaluation Lessons Learned

Clinical Data Evaluation Lessons Learned Clinical Data Evaluation Lessons Learned Laurel Macomber MS, PMP, RAC BSI Product Expert, General Devices Presented by Ibim Tariah Ph.D Technical Director - Healthcare Copyright 2015 BSI. All rights reserved.

More information

INSTRUCTIONS FOR USE FOR:

INSTRUCTIONS FOR USE FOR: INSTRUCTIONS FOR USE FOR: en English bg Български cz Čeština dk Dansk nl Nederlands ee Eesti fi Suomi fr Français de Deutsch gr Ελληνικά hu Magyar it Italiano lt Lietuvių no Norsk pl Polska pt Português

More information

Fungal graft infections: Case report and review of the literature

Fungal graft infections: Case report and review of the literature Fungal graft infections: Case report and review of the literature William Doscher, M.D., K. V. IC, a-ishnasastry, M.D., and Stephen L. Deckoff, M.D., Flushing, N.Y. Fungal intravascular graft infections

More information

How to Prevent Central Line- Associated Sepsis in the NICU

How to Prevent Central Line- Associated Sepsis in the NICU How to Prevent Central Line- Associated Sepsis in the NICU Professor of Pediatrics, Molecular Virology and Microbiology International Symposium on Neonatology Texas Children s Hospital Sao Paulo, Brazil

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS FREQUENTLY ASKED QUESTIONS Table of Contents GORE ACUSEAL Vascular Graft Properties What is the GORE ACUSEAL Vascular Graft?...2 What is unique about the GORE ACUSEAL Vascular Graft?...3 What are the

More information

Protect the Neck. Lieven Maene, MD. Marc Bosiers Koen Deloose Joren Callaert. Patrick Peeters Jürgen Verbist. Lieven Maene Roel Beelen.

Protect the Neck. Lieven Maene, MD. Marc Bosiers Koen Deloose Joren Callaert. Patrick Peeters Jürgen Verbist. Lieven Maene Roel Beelen. A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Protect the Neck Patrick Peeters Jürgen Verbist OLV Hospital, Aalst Lieven Maene Roel Beelen R.Z. Heilig

More information

Financial impact of endoscopic vein harvest for infrainguinal bypass

Financial impact of endoscopic vein harvest for infrainguinal bypass Financial impact of endoscopic vein harvest for infrainguinal bypass Karl A. Illig, MD, Jeffrey M. Rhodes, MD, Yaron Sternbach, MD, and Richard M. Green, MD, Rochester, NY Purpose: The purpose of this

More information

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) PACIFIC LUTHERAN UNIVERSITY TACOMA, WA PHONE: (253) FAX: (253)

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) PACIFIC LUTHERAN UNIVERSITY TACOMA, WA PHONE: (253) FAX: (253) INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) PACIFIC LUTHERAN UNIVERSITY TACOMA, WA 98447-0001 PHONE: (253)535-7126 FAX: (253) 535-8760 PROTOCOL FOR ANIMAL CARE AND USE IACUC Approval Form (Created

More information

IMPROVED SURGICAL OUTCOMES

IMPROVED SURGICAL OUTCOMES IMPROVED SURGICAL OUTCOMES Through advanced access and visualization Diane Am aral, BSN Clinical Line Manager and Robotic Coordinator Hoag Mem orial Hos pital Newport Beac h, Calif ornia CONTINUING EDUCATION

More information

HANDLING OF WRIGHT MEDICAL DISPOSABLE PROPHECY TM ANKLE INSTRUMENTS

HANDLING OF WRIGHT MEDICAL DISPOSABLE PROPHECY TM ANKLE INSTRUMENTS HANDLING OF WRIGHT MEDICAL DISPOSABLE PROPHECY TM ANKLE INSTRUMENTS 153290-0 The following languages are included in this packet: English (en) For additional languages, visit our website www.wright.com

More information

Vision of optimal vascular surgical training in the next two decades: Strategies for adapting to new technologies

Vision of optimal vascular surgical training in the next two decades: Strategies for adapting to new technologies Vision of optimal vascular surgical training in the next two decades: Strategies for adapting to new technologies Wesley S. Moore, MD, G. Patrick Clagett, MD, Robert W. Hobson II, MD, Jonathan B. Towne,

More information

Effect of improved endograft design on outcome of endovascular aneurysm repair

Effect of improved endograft design on outcome of endovascular aneurysm repair Effect of improved endograft design on outcome of endovascular aneurysm repair Francesco Torella, MD, FRCS, on behalf of the EUROSTAR Collaborators, Liverpool, England Objective: This study was undertaken

More information

KEY TO INNOVATION AT VASCUTEK JAPAN MATTERS FEBRUARY 7TH 2014

KEY TO INNOVATION AT VASCUTEK JAPAN MATTERS FEBRUARY 7TH 2014 KEY TO INNOVATION AT VASCUTEK JAPAN MATTERS FEBRUARY 7TH 2014 VASCUTEK LTD : Background Manufacturer of synthetic vascular grafts In business since 1982 Over 500 employees Turnover around 70 million No.

More information

Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis.

Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin Bergqvist D, Lindgren B, Matzsch T Record Status This is a critical abstract

More information

CapSure Permanent Fixation System

CapSure Permanent Fixation System CapSure Permanent Fixation System Permanent Fixation Redefined Advancing the Fixation Experience Recipient of 2015 SLS Innovations of the Year recognition. SOFT TISSUE REPAIR Right Procedure. Right Product.

More information

Regulatory hurdles and opportunities

Regulatory hurdles and opportunities Regulatory hurdles and opportunities Professor Roger Finch Nottingham University Hospitals & University of Nottingham, UK Drug licensing and regulation Mandatory for market authorisation Supports the public

More information

TITLE: Recombinant Human Thrombin: Clinical Effectiveness And Cost-Effectiveness

TITLE: Recombinant Human Thrombin: Clinical Effectiveness And Cost-Effectiveness TITLE: Recombinant Human Thrombin: Clinical Effectiveness And Cost-Effectiveness DATE: 08 November 2010 CONTEXT AND POLICY ISSUES: Excessive bleeding during surgical procedures can lead to increased morbidity

More information

Development of a Finite Element Model to Analyse the Proximal Ring of an Endovascular Device

Development of a Finite Element Model to Analyse the Proximal Ring of an Endovascular Device Development of a Finite Element Model to Analyse the Proximal Ring of an Endovascular Device Emma McCummiskey Department of Mechanical Engineering University of Strathclyde Glasgow, UK. Overview Medical

More information

Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852

Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 May 24, 2012 Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 Re: Comments on Docket #FDA- 2012 D 0148; Draft Guidance for Industry

More information

Journal of Biomedical Materials Research, Vol. 20, (1986) John Wiley & Sons, Inc.

Journal of Biomedical Materials Research, Vol. 20, (1986) John Wiley & Sons, Inc. Journal of Biomedical Materials Research, Vol. 20, 861-865 (1986) 0 1986 John Wiley & Sons, Inc. 862 Characterization of morphologic and mechanical properties of surgical mesh fabrics C. C. Chu, B. Pourdeyhimi,*

More information

/94/$ /1/47126

/94/$ /1/47126 Comparison of the resistance to infection of intestinal submucosa arterial autografts versus polytetrafluoroethylene arterial prostheses in a dog model Stephen F. Badylak:, DVM, PhD, MD, Arthur C. Coffey,

More information

Median Sternotomy Closure Utilizing Platelet Concentrate BIOLOGICS

Median Sternotomy Closure Utilizing Platelet Concentrate BIOLOGICS Median Sternotomy Closure Utilizing Platelet Concentrate BIOLOGICS This brochure is for International use only. It is not for distribution in the United States. The Surgical Procedure: Median Sternotomy

More information

Emorroidectomia e Nuove Tecnologie. A. Amato Struttura S. di Colonproctologia Ospedale di Sanremo

Emorroidectomia e Nuove Tecnologie. A. Amato Struttura S. di Colonproctologia Ospedale di Sanremo Emorroidectomia e Nuove Tecnologie A. Amato Struttura S. di Colonproctologia Ospedale di Sanremo Incidence and Complications of Operative Therapy Retrospective review Bleday R et al. Dis Colon Rectum 1992;

More information

Perioperative Enterprise Committee Surgical Site Infection Report. May 15, 2008

Perioperative Enterprise Committee Surgical Site Infection Report. May 15, 2008 Perioperative Enterprise Committee Surgical Site Infection Report May 5, 8 VUH ORs OB Infections, by Quarter Superficial SSI 8 Overall SSI Active Surveillance 7. 8 7 5 3 Q3 5 Q Q 7 Q 7 Q3 7 Q 7 5. Q 8

More information

TÁMOP /2/A/KMR

TÁMOP /2/A/KMR HEALTH ECONOMICS HEALTH ECONOMICS Sponsored by a Grant TÁMOP-4.1.2-08/2/A/KMR-2009-0041 Course Material Developed by Department of Economics, Faculty of Social Sciences, Eötvös Loránd University Budapest

More information

Recommended Agent First alternative for β-lactam allergy Alternative Agents (in order of preference) document β-lactam allergy for SCIP)

Recommended Agent First alternative for β-lactam allergy Alternative Agents (in order of preference) document β-lactam allergy for SCIP) Surgical Prophylaxis Guideline Updates Wadley Regional Medical Center Surgery and Trauma Committee, July 22, 2014 Pharmacy and Therapeutics Committee, August 2014 Compiled by: Andrea C Jarzyniecki, Pharm

More information

Laminar flow in orthopaedic operations - Essential if you can afford it. Peter Hoffman Consultant Clinical Scientist Public Health England

Laminar flow in orthopaedic operations - Essential if you can afford it. Peter Hoffman Consultant Clinical Scientist Public Health England Laminar flow in orthopaedic operations - Essential if you can afford it Peter Hoffman Consultant Clinical Scientist Public Health England Up until the 1950s in the UK (and elsewhere) Surgical instruments

More information